<DOC>
	<DOCNO>NCT00048633</DOCNO>
	<brief_summary>The primary objective phase II study ass XR9576 , selective MDR-1 inhibitor , able reverse primary doxorubicin taxane resistance advance breast cancer . Clinical activity measure objective tumor response rate observe treatment XR9576 combination taxane anthracycline contain chemotherapy patient previously resistant agent ( ) . The secondary objective study assess biological activity XR9576 evaluate MDR-1 expression tumor . The MDR-1 inhibitory activity XR9576 evaluate serial sestamibi scan tumor . MDR-1 expression detect immunohistochemistry .</brief_summary>
	<brief_title>Phase II Study Evaluate Tariquidar ( XR9576 ) , Selective MDR-1 Inhibitor , Chemotherapy Resistant Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Histologically proven breast cancer primary resistance anthracyclines ( doxorubicin , epirubicin ) taxane ( paclitaxel , docetaxel ) . Primary chemotherapy resistance define purpose protocol follow : 1 . Progression minimum 1 cycle therapy , 2 . Stable disease minimum 2 cycle therapy , 3 . Relapse within 6 month completion anthracycline or/and taxane contain chemotherapy regimen . Patients anthracycline/taxane resistance INOPERABLE , locally advanced breast cancer eligible . Patients must measurable disease define RECIST criterion breast/nodal region distant organ site ( ) . There limit prior hormonal therapy one prior chemotherapy metastatic breast cancer allow . Patients may receive concomitant bisphosphonate therapy bone metastasis . Patients may continue Herceptin previously start . Herceptin add chemotherapy regimen new agent time XR9576 initiate . Patients much recover acute toxic effect prior therapy . Zubrod performance status less equal 2 . Adequate bone marrow function : platelet great equal 100,000/mm3 , ANC great equal 1500 cells/mm3 , hemoglobin great equal 8g/dl . Normal renal function : creatinine le equal 2.0 mg/dl . Adequate liver function : bilirubin le equal 1.5 mg/dl . Transaminase ( SGOT ) alkaline phosphatase must less equal 1.5 x upper limit normal absence bone liver metastasis , less equal 2.5 x upper limit normal presence radiologically apparent liver metastasis bone metastasis , respectively . Female patient must nonlactating use adequate contraception premenopausal . BetaHCG check premenopausal patient clinically indicate . Patients brain metastasis whose disease remain stable 3 month complete therapy brain eligible . Written informed consent . Exclusion criterion : More 1 chemotherapy regimen metastatic breast cancer . Patients relapse 6 month completion anthracycline taxane therapy . Current treatment nontaxane , nonanthracycline base chemotherapy . Uncontrolled psychiatric , social ( addictive ) disorder would preclude obtain informed consent patient participation study . Clinical contraindication continue anthracycline taxane therapy . For patient show primary resistance anthracyclines include great 300 mg/m2 maximum lifetime cumulative dose doxorubicin , symptomatic heart failure , history heart failure , recent myocardial infarction ( le 6 month ) leave ventricular ejection fraction normal range . For patient primary resistance taxanes , persistent grade 2 great neuropathy ( neuropathy interferes function ) . Patients operable primary breast cancer eligible . Patients develop primary resistance chemotherapy combination doxorubicin/docetaxel .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Chemotherapy resistance advance breast cancer</keyword>
</DOC>